From POZ online…
HIV treatment has entered an exciting new era as Canada has become the first nation in the world to approve ViiV Healthcare’s monthly long-acting injectable antiretroviral (ARV) regimen Cabenuva (cabotegravir/rilpivirine)—the first complete regimen for treating the virus that does not require daily pills.
In late December, the Food and Drug Administration (FDA) held up approval of the regimen, citing concerns over its manufacturing process. In turn, ViiV indicated it was working closely with the FDA to address those concerns and ultimately bring Cabenuva to market in the United States.
ViiV first applied for FDA approval of Cabenuva in April 2019.